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1 Zusammenfassung 
1.1 Hintergrund 
Der Adenosindiphosphat-Rezeptor P2Y12 bewirkt Plättchenaggregation und trägt zur Bildung 
arterieller Thrombosen bei. P2Y12-Antagonisten, wie Clopidogrel und Ticagrelor, werden 
daher zur Prävention von Herzinfarkten und Schlaganfällen in Patienten mit einem akuten 
Koronarsyndrom (AKS) verwendet. Ticagrelor war Clopidogrel in der Reduktion der Mortalität 
in diesen Patienten überlegen und die zugrunde liegenden Mechanismen sind nicht 
vollständig geklärt. Die arterielle Thrombose ist das zentrale Ereignis in der Entwicklung des 
AKS und das Gefässendothel ist wesentlich an dessen Entstehung beteiligt. Mögliche Effekte 
von P2Y12-Antagonisten auf das Endothel und seinen prokoagulatorischen Faktoren, 
insbesondere dem Gewebefaktor, wurden bisher nicht untersucht. Patienten mit AKS haben 
häufig Komorbiditäten wie Vorhofflimmern (VHF) und benötigen daher eine zusätzliche 
antikoagulatorische Therapie zum Schutz vor Embolien kardialer Thromben aus dem linken 
Herzohr. Ähnlich dem Endothel, führt eine Aktivierung des Endokards zu einer 
Überexpression des Gewebefaktors sowie des Plasminogenaktivator-inhibitors-1, welche zur 
Thrombogenität in Patienten mit Vorhofflimmern beitragen. Ob bestimmte P2Y12-
Antagonisten antithrombotische Eigenschaften auf das Endokard linker Herzohren aufweisen 
und dadurch die Thrombogenität in Patienten mit VHF reduzieren könnten, wurde bisher 
nicht untersucht. 
 
1.2 Material und Methoden 
Menschliche aortale Endothelzellen wurden mit Ticagrelor oder mit dem aktiven Metaboliten 
von Clopidogrel behandelt und mit Tumor-Nekrose-Faktor-alpha (TNF-α) stimuliert. 
Anschliessend wurden die Expression und Aktivität des Gewebefaktors sowie die zugrunde 
liegenden molekularen Mechanismen erforscht. Zusätzlich wurden C57BL/6 Mäuse mit 
Ticagrelor oder Clopidogrel behandelt und die Expression des endothelialen Gewebefaktors 
sowie die Bildung arterieller Thrombosen nach photochemische Schädigung des Endothels 
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der Halsschlagadern untersucht. Schliesslich gewannen wir Endokardzellen aus linken 
Herzohren von 14 Patienten mit VHF, welche sich einer elektiven Herzoperation unterzogen. 
Diese wurden mit Ticagrelor oder mit dem aktiven Metaboliten von Clipidogrel behandelt und 
mit TNF-α stimuliert bevor die Expression und Aktivität des Gewebefaktors und des 
Plasminogenaktivator-inhibitors-1 analysiert wurden. 
 
1.3 Ergebnisse 
Ticagrelor, im Gegensatz zum aktiven Metaboliten von Clopidogrel, verringerte die TNF-α-
induzierte Expression und Aktivität des Gewebefaktors durch proteasomale Degradierung  
unter Einbezug der Signalmoleküle Phosphoinositide-3-Kinase und p70s6 Kinase und 
unabhängig vom P2Y12 Rezeptor sowie dem equilibrative nucleoside transporter 1 (ENT1). 
Wie in unseren in vitro Experimenten, reduzierte Ticagrelor, nicht aber Clopidogrel, die 
Expression des endothelialen Gewebefaktors in Mausarterien und verlängerte die Zeit bis zur 
Entstehung arterieller Thrombosen. Dabei waren die Plättchenhemmung, die 
Gewebefaktoraktivität im Plasma und die systemische Koagulation in beiden Gruppen 
vergleichbar. In Endokardzellen linker Herzohren von Patienten mit Vorhofflimmern 
verminderte Ticagrelor, nicht aber Clopidogrel, die TNF-α-induzierte Expression und Aktivität 
des Gewebefaktors und des Plasminogenaktivator-inhibitors-1.  
 
1.4 Konklusionen 
Ticagrelor, nicht aber Clopidogrel, weist lokale antithrombotische Eigenschaften auf das 
Endothel auf und reduziert die Entstehung von arteriellen Thrombosen im Vergleich zu 
Clopidogrel. Zudem zeigt Ticagrelor, nicht aber Clopidogrel, lokale antithrombotische Effekte 
im Endokard linker Herzohren von Patienten mit VHF auf. Die antithrombotischen 
Eigenschaften von Ticagrelor tragen möglicherweise zur Reduktion der Mortalität von 
Patienten mit AKS in klinischen Studien bei und vermindern allenfalls das Risiko für 
systemische Thromboembolien in Patienten mit Vorhofflimmern.  
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2 Summary 
2.1 Background 
The adenosine diphosphate receptor P2Y12 mediates platelet aggregation and contributes to 
arterial thrombus formation; therefore, P2Y12 antagonists, such as clopidogrel and ticagrelor, 
are used to prevent myocardial infarction and stroke in patients with acute coronary 
syndromes (ACS). Yet, ticagrelor was found superior over clopidogrel in decreasing mortality 
in these patients and the underlying mechanisms are not entirely understood. Arterial 
thrombosis is the crucial step in ACS and the endothelium plays a pivotal role in mediating 
thrombus formation. However, possible off-target effects of P2Y12 antagonists on the 
endothelium and its key procoagulant factors such as tissue factor (TF), have not yet been 
investigated. Frequently, patients with ACS have comorbidities such as atrial fibrillation (AF) 
requiring anticoagulant therapy to prevent embolism of thrombi originating from left atrial 
appendages (LAA). Similar to endothelial cells, activation of LAA endocardial cells induces 
procoagulant TF and plasminogen activator inhibitor-1 (PAI-1) expression favouring 
thrombus formation in patients with AF. Whether certain P2Y12 antagonists possess 
antithrombotic properties on endocardial cells and may reduce thrombogenicity in AF 
patients has not yet been investigated. 
 
2.2 Material and methods  
Human aortic endothelial cells (HAECs) were incubated with ticagrelor or clopidogrel active 
metabolite (CAM) before stimulation with tumor necrosis factor-alpha (TNF-α); next, TF 
protein expression and enzyme activity as well as the underlying molecular mechanisms 
were investigated. Additionally, C57BL/6 mice were treated with ticagrelor or clopidogrel 
before endothelial TF expression was determined in common carotid arteries and 
photochemical-induced arterial thrombosis was compared between the groups. Finally, 
endocardial cells were isolated from LAA of 14 patients with AF undergoing elective cardiac 
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surgery. Endocardial cells were treated with ticagrelor or CAM and stimulated with TNF-α 
and TF as well as PAI-1 expressions and enzyme activities were analysed. 
 
2.3 Results 
Ticagrelor, unlike CAM, decreased TNF-α-induced TF activity and expression via 
proteasomal degradation in HAECs. These effects were mediated via the signalling 
molecules phosphoinositide 3-kinase and p70s6 kinase and independently of the P2Y12 
receptor and the equilibrative nucleoside transporter 1 (ENT1). Likewise, ticagrelor, but not 
clopidogrel, reduced endothelial TF expression in common carotid arteries of C57BL/6 mice 
and prolonged time to arterial thrombosis; meanwhile, platelet inhibition, plasma TF activity 
and systemic coagulation were comparable between the two groups. In LAA endocardial 
cells from AF patients, ticagrelor, unlike CAM, decreased TNF-α-induced TF and PAI-1 
protein expressions and enzyme activities. 
 
2.4 Conclusions 
Ticagrelor, but not clopidogrel, displays local antithrombotic properties on the endothelium 
and, compared with clopigorgel, reduces arterial thrombosis. Likewise, ticagrelor, but not 
CAM, exhibits local antithrombotic properties in AF patients by reducing expressions and 
activities of TF and PAI-1 in LAA endocardial cells. The specific antithrombotic properties of 
ticagrelor may contribute to the reduced mortality in ACS patients observed in clinical trials 
and may prevent systemic thromboembolism in patients with AF.  
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3 Introduction 
3.1 Epidemiology of cardiovascular disease 
Cardiovascular (CV) disease (CVD), including coronary heart disease and stroke, is the 
leading cause of death in Europe (Fig. 1)1, the United States of America2 and worldwide.3 In 
Europe, 4 million deaths per year are attributed to CVD, thereby representing 45 % of all 
deaths1. Interestingly, absolute and relative numbers of CV mortality are greater in women 
than in men, which is due to a higher number of cerebrovascular and “other CVD”, whereas 
coronary heart disease is comparable among both sexes (Fig. 1).1 
 
 
 
 
 
 
Figure 1. Deaths due to major causes in (A) men and (B) women in Europe. Source:1  
 
From 1990 to 2013, CV mortality increased from 12.3 to 17.3 million deaths worldwide, 
representing 25.9 % and 31.5 % of all non-communicable diseases, respectively.1 One 
explanation for this observation represents the ageing population4 since age is a major risk 
factor for the development of CVD.5 Ageing results from improved healthcare6 and better 
lifestyle conditions7 and is expected to continue in the near future causing substantial 
increase of disease burden and healthcare costs.4 Besides coronary heart disease and 
stroke, atrial fibrillation represents the most common cardiac arrhythmia with a prevalence of 
1.5 – 2 % in the general population and occurs at an average age of 75 – 85 years.8 In 
addition to the increased risk for mortality, thromboembolic complication, such as stroke, 
cause a significant disease burden and healthcare costs, which are estimated to further 
increase in the next decades.8  
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3.2 Endothelial function and dysfunction 
Vessel wall 
The vascular wall consists of an inner layer of endothelial cells, followed by vascular smooth 
muscle cells (VSMC) and adventitial cells9 (Fig. 2). The endothelial layer represents a roughly 
0.2 µm thick monolayer covering the whole vasculature and thereby an area of approximately 
3000 – 6000 m2, whereas the majority of cells are considered microvascular endothelial cells 
covering particularly capillaries.10 The volume of the entire endothelium is comparable to the 
volume of the liver.11 The endothelium preserves blood fluidity by preventing thrombus 
formation, adjusts tissue perfusion by regulating vascular tone, regulates vascular 
permeability and inflammatory responses, and plays a pivotal role during angiogenesis.11 
 
 
Figure 2. Arterial wall structure. The arterial wall is divided into the tunica intima containing ECs, the tunica 
media containing VSMCs and the tunica adventitia containing adventitial cells. EC = endothelial cell, VSMC = 
vascular smooth muscle cell. Source:9  
 
Endothelial function 
In healthy conditions, the endothelium prevents thrombus formation by physically separating 
platelets and coagulation factors from subendothelial prothrombotic mediators, such as 
collagen and tissue factor (TF)12, and by expressing anticoagulant mediators such as nitric 
oxide (NO)13,14, prostacyclin (PGI2)15, ectonucleotidase CD3916, tissue factor pathway inhibitor 
(TFPI)17 and antithrombin III18 among others. During resting state, endothelial cells do not 
interact with leukocytes since expression of adhesion molecules is down regulated and 
  11 
chemokines are not secreted.19 Vascular tone is regulated via various vasoactive substances 
causing vasodilatation, such as NO, prostacyclin, adenosine and hydrogen peroxide (H2O2) 
or mediators causing vascular contraction, such as thromboxane A2, endothelin, angiotensin 
II, superoxide anion (O2-) but also hydrogen peroxide.11  
 
Endothelial dysfunction and reactive oxygen species 
Endothelial dysfunction is characterised by reduced vasodilatatory properties or a shift 
toward a proinflammatory or a prothrombotic state20; it is associated with aging, diabetes, 
hypertension and atherosclerosis11 and predicts CV outcome in patients with peripheral 
arterial disease21, atherosclerosis22, ACS23 and heart failure.24 
 
Despite the complexity of the pathogenic mechanisms leading to ED, oxidative stress is 
considered a central player in this respect.11 Relevant reactive oxygen species (ROS) for 
vascular pathology include NO, superoxide anion, hydrogen peroxide and peroxynitrite 
(ONOO-).25 NO is produced by endothelial NO synthase26 and by inducible NO synthase in 
endothelial cells, macrophages and VSMCs during inflammatory state.27 It causes 
endothelial-dependent vasodilatation13,14, inhibits platelet adhesion28 and aggregation29, and 
adhesion of leukocytes by inhibiting the expression of adhesion molecules.20 Superoxide 
anion is produced by various enzymes including NO synthase, nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase and xanthine oxidase30 and occurs in all cell types. 
In the presence of superoxide anion, NO reacts to ONOO-, which causes oxidation of 
proteins, deoxyribonucleic acids and lipids31 leading to the formation of oxidized low-density 
lipoprotein (LDL)25 among others. Alternatively, O2- is reduced to H2O2 by superoxide 
dismutase and finally dismutated to water and oxygen by catalase or glutathione 
peroxidase.11 In the presence of copper and ion or superoxide however, H2O2 forms highly 
reactive hydroxyl radicals (OH).11  
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ROS affect endothelium-derived vasorelaxation by uncoupling NO synthase thus reducing 
the bioavailability of NO and by inhibiting the downstream NO target guanylyl cyclase.11 Also, 
ROS cause vasoconstriction by multiple mechanisms including increased release of calcium 
from the sarcoplasmatic reticulum32 and activation of cyclooxygenase-1 and subsequent 
production of endothelium-derived contracting factors.33 Further, ROS induce the expression 
of endothelial adhesion molecules34 and monocyte chemoattractant protein-135 enhancing 
leukocyte-endothelium interaction and thereby modulating inflammatory responses.  
 
3.3 Atherosclerosis 
Atherosclerosis may be defined as a thickening and loss of elasticity of arterial walls due to 
atherosclerotic plaque formation36,37 typically affecting the subendothelial intima of large and 
medium-sized arteries.38 Atherosclerotic plaques consist of connective tissue, such as 
collagen and proteoglycans, cholesterol and phospholipids as well as cellular components 
including macrophages/foam cells, T-lymphocytes and VSMC36-38 (Fig. 3). 
 
ED, a shift of the endothelium towards a prothrombotic and proinflammatory state with a 
reduced vasodilatory capacity, is driven by classical CV risk factors such as dyslipidaemia, 
diabetes and hypertension11 and is considered a precursor of atherosclerosis.39 ED causes 
increased permeability and leukocytes adhesion to the endothelium40 (Fig 3 B). During the 
early phase of plaque formation, intimal thickening occurs due to accumulation of connective 
tissue, particularly proteoglycans, followed by lipid deposition41 (Fig. 3C). 
Lipoproteins containing apolipoprotein B, such as LDL and presumably lipoprotein(a), are of 
particular importance for plaque development. LDL accumulates in the subendothelial space 
through binding to extracellular connective tissue, i.e. proteoglycans.42 Interaction of LDL with 
proteoglycans depends on LDL size and density, whereas small and dense particles possess 
higher binding capacities.42 LDL retention increases susceptibility of multiple lipoprotein 
modifications such as self-aggregation, cleavage and oxidation, thereby transforming LDL 
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particles proatherogenic, finally, leading to the progression of atherosclerotic plaque 
formation.42 Indeed, oxidized LDL has been demonstrated in human atherosclerotic 
plaques.43 From a clinical perspective, plasma levels of LDL strongly correlate with the 
development of atherosclerosis.44 Consistently, reduction of LDL has been shown to reduce 
the risk for CV events45 strongly supporting a causal concept between LDL cholesterol and 
atherosclerosis development and progression. 
 
 
Figure 3. Atherosclerosis development. A) Healthy arterial wall. B) Initiation of atherosclerosis by 
transmigration of leukocytes and subsequent foam cell formation of monocytes through lipid uptake. C) 
Progression of atherosclerotic lesion through VSMC proliferation and migration, production of extracellular matrix 
connective tissue, apoptosis of macrophages and finally, accumulation of apoptotic bodies forming a necrotic 
core. D) Fibrous cap rupture and subsequent formation of an arterial thrombus through interaction of platelets and 
coagulation factors. Source: 36 
 
Endothelial transmigration of leukocytes including monocytes and T-lymphocytes (Fig. 3B) 
depends on the expression of endothelial adhesion molecules40 and is mediated by 
chemoattractants46,47, which can be stimulated by oxidized LDL.46 Furthermore, both LDL 
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aggregation48 and oxidation stimulate LDL uptake in macrophages49 through scavenger 
receptors50 finally leading to LDL degradation, intracellular lipid deposition and foam cell 
formation.51 Scavenging of oxidized LDL through macrophages may reduces detrimental 
effects on surrounding cells, such as endothelial cells or VSMC; nevertheless, progressive 
lipid deposition magnifies inflammatory responses and overcomes such compensatory 
mechanisms of macrophages.40 After adherence and migration, T-lymphocytes are in turn 
activated by macrophages through presentation of oxidized LDL52 and secretion of cytokines 
including interferon-y and tumor necrosis factor-alpha (TNF-α).53 Likewise, monocytes that 
transform to proinflammatory M2 macrophages secrete proinflammatory cytokines54 thereby 
further enhancing the inflammatory response. Some foam cells undergo apoptosis followed 
by necrosis and release lipids, which together with necrotic cell components form the necrotic 
core in atherosclerotic plaques.55 
 
In addition to monocytes and leukocytes, VSMC contribute to atherosclerotic plaque 
formation either by proliferation of VSMC in the intima, present in human arteries56, or 
migration from the VSMC layer of the vessel37 (Fig. 3C). Recently it has been proposed that 
in addition to local VSMC, bone marrow-derived stem cells contribute to atherosclerotic 
vascular pathology by homing, differentiation and migration.57 VSMC secrete connective 
tissue like collagen and elastin, which together build the fibrous cap covering the 
atherosclerotic plaques and preventing plaque rupture36 (Fig. 3D).  
 
3.4 Tissue factor and initiation of the coagulation cascade 
Tissue factor 
TF is a transmembrane glycoprotein, which initiates the extrinsic coagulation cascade by 
binding coagulation factor VII58, thereby activating factor IX and X59 finally resulting in 
thrombin and subsequent fibrin formation.60 Full length TF is a 47-kDa protein encoded by 6 
exons located at chromosome 1 and comprises 263 amino acids, whereas the extracellular 
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domain consists of residues 1 – 219, the transmembrane domain of residues 220 – 242 and 
the cytoplasmic domain of residues 243 – 263.58 The factor VII binding side is located at the 
extracellular domain.61 In addition to full length TF, alternatively spliced TF has been 
described, which lacks exon 5.62 Therefore, alternatively spliced tissue factor contains only 
206 amino acids, whereas residues 1 – 166 are identical to full length TF62 representing its 
extracellular domain and contain the factor VII binding side;61 thus alternatively spliced TF is 
considered to be able to initiate coagulation.62 The remaining residues 167 – 206 differ from 
full length TF due to a frameshift mutation and represent a unique C-terminus.62 Since the 
transmembrane domain is not expressed, alternatively spliced TF is soluble and circulates in 
blood.62 Possible sources of alternatively spliced TF include monocytes62 and endothelial 
cells.63 Alternatively spliced TF has been detected in human thrombi and is believed to 
contribute to thrombogenicity;62 however, its procoagulant activity was not proven by 
others64,65 and therefore its role in thrombosis is unclear. In addition to active cell surface TF, 
inactive and so called “encrypted” TF has been described.66 Like active TF, it binds factor VII, 
however, does not activate factor X sufficiently to prompt procoagulant activity.66 
Transformation to the active form is mediated by protein-disulfide isomerase67 and has been 
shown to be crucial for fibrin generation and thrombus formation in mice.68 
 
TF is expressed in endothelial cells69, VSMCs, the adventitia70, monocytes71, platelets and on 
circulating TF-containing microparticles released from platelets72,73, endothelial cells and 
monocytes.74 Furthermore it is expressed not only in the necrotic core of atherosclerotic 
plaques, but also in macrophages and the endothelium covering human atherosclerotic 
plaques.70,75,76 In physiological conditions only spare amount of TF are found in endothelial 
cells; however, during pathological conditions, such as high shear flow as occurring in a 
stenosed vessel77 and in the presence of various inflammatory cytokines such TNF-α and 
interleukin 178 as well as thrombin79, CD40 ligand80 and oxidized LDL81, TF expression is 
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increased in endothelial cells. Likewise, interleukin 1 induces tissue factor expression in 
monocytes82 and CD40 ligand in monocytes83 and VSMCs.84  
 
Initiation of the coagulation cascade 
Tissue factor represents a cellular receptor for the plasma serine protease factor VII or the 
activated form, factor VIIa85 (Fig. 4). Binding of TF enhances factor VII activation to VIIa86 and 
binding of TF is essential to increases factor VIIa enzyme activity in order to activate factor IX 
and factor X to factor IXa and Xa, respectively.85 Activation of factor VII to factor VIIa is further 
mediated by factor IXa and Xa87 as well as factor VIIa itself.88 Next, factor Xa forms the 
prothrombinase complex with factor Va on TF-containing cells,89 thereby transforming small 
amounts of prothrombin to thrombin, which subsequently amplifies the coagulation signal by 
activating factor V, VIII and XI on platelet surfaces90 (Fig. 4). Finally, thrombin transforms 
fibrinogen to fibrin91 and activates platelets by cleavage of protease-activated receptors.92 
 
 
Figure 4. Coagulation system. TF binds activated factor VII (VIIa) and activates factor X and factor IX. Factor Xa 
leads to the production of small amounts of thrombin, which in turn activates factor V (cofactor of factor X), factor 
VIII (cofactor of factor IX) and factor XI. Factor XIa further enhances factor IX activation. Factor IXa together with 
cofactor VIIIa (tenase complex) increase factor X activation. Finally, factor Xa binds factor Va (prothrombinase 
complex) and increases thrombin production substantially. TF = tissue factor. Source:86 
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In order to preserve an antithrombotic endothelial cell surface in physiologic condition, TFPI 
counteracts TF-mediated activation of coagulation and subsequent thrombus formation93. 
TFPI is expressed in endothelial cells under quiescent conditions and, like TF, can be 
upregulated upon activation by inflammatory cytokines.94 TFPI directly inhibits factor Xa,93 
most efficiently if factor Xa is integrated in the prothrombinase complex with factor Va, calcium 
ions and phospholipids.95 In addition, TFPI inhibits the TF/factor VII(a) through complexing 
with TF/factor VII(a) and Xa.93 
 
Experimental and clinical studies 
Experimental data revealed reduced arterial thrombus formation in low-TF expressing mice 
thus suggesting a pivotal role of vascular TF in thrombus formation.96 Transgenic mice 
deficient in murine TF and expressing 1% of human tissue factor, revealed prolonged arterial 
occlusion times after photochemical injury of the carotid artery using bengal rose.96 Neither 
did transplantation of low-TF bone marrow to wild-type animals increase, nor did 
transplantation of wild-type bone marrow to low-TF animals decrease arterial occlusion times 
confirming the relevance of vascular- rather than blood cell-derived TF in arterial thrombus 
formation.96 In addition, anti-TF antibody treated rabbits displayed reduced arterial thrombus 
formation after injury and subsequent stenosis of the common carotid artery.97 In clinical 
studies, increased levels of TF have not only been associated with cardiovascular risk factors 
including smoking98, hypertension99, diabetes100 and dyslipidaemia101 but also with acute 
coronary syndrome (ACS)102 emphasizing the clinical relevance of TF.  
 
3.5 Platelets and the P2Y12 receptor 
Platelets 
Human platelets are anucleated blood cells derived from bone marrow magakaryocytes with 
an average life span of 9 to 10 days.103 Despite the lack of DNA, platelets contain 
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megakaryocyte-derived messenger RNA104 and are capable of protein synthesis.105 One-
hundred-fifty x 109 to 400 x 109 human platelets per litre of blood103 are present in the 
circulation, which are in turn surrounded by 3000 – 6000 m2 of endothelial surface.10 In 
physiological conditions, the endothelium prevents platelet adhesion and aggregation by 
separating platelets from the subendothelial matrix, by inhibiting platelets through NO13,14 and 
PGI215 and by inhibiting platelet agonists through antithrombin III18 and adenosine 
diphosphate (ADP) metabolism, among others.106 During resting state platelets appear 
round/oval whereas upon endothelial damage, platelets adhere to the side of injury, become 
activated and aggregate, which results in profound shape changes such as cellular 
spreading.12 Platelet are crucial to sustain haemostasis in case of injury; however, they may 
cause thrombus formation, subsequent vascular occlusion and tissue ischemia in 
pathological conditions.12  
 
In case of vascular injury or endothelial disruption, subendothelial extracellular matrix 
containing different types of collagens, von Willebrand factor (vWF), fibronectin and laminin is 
exposed to the blood stream107 (Fig. 5A). In high shear conditions as observed in the arterial 
circulation or in stenosed vessels, binding of the platelet receptor glycoprotein (GP) Ibα, part 
of the GPIb-V-IX complex, to extracellular vWF or plasma-derived vWF bound to 
subendothelial collagen, is crucial for platelet tethering.108 Yet, additional interactions of 
platelet GPVI and/or integrin α2ß1 with collagen, platelet integrin α5ß1 with fibronectin or 
platelet integrin α6ß1 with laminin is required for platelet adhesion.109 Adhesion of platelets to 
extracellular matrix proteins, particularly collagen and vWF, activates the platelet integrin 
αIIbß3 receptor allowing binding of several ligands such as soluble vWF, fibrinogen and fibrin 
and by that cross-linkage of platelets, a key step in firm adhesion and platelet 
aggregation12,107 (Fig. 5B). In parallel platelets produce thromboxane A2 and release dense 
granules containing ADP and α granules containing vWF, fibrinogen, fibronectin, p-selectin 
and interleukin 1 beta (Fig. 5A), which amplify platelet activation (ADP, thromboxane), 
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facilitate platelet-endothelium interaction (vWF, fibronectin), platelet-leukocyte interaction 
(fibronectin, fibrinogen p-selectin), leukocyte-endothelium interaction (p-selectin, interleukin 1 
beta), platelet aggregation (vWF, fibrinogen) and finally, fibrin clot formation (fibrinogen, 
factor V).12,109  
 
 
Figure 5. Platelet activation and aggregation. A) Platelet tethering to the vessel wall is mediated via GPIb-V-IX 
binding to subendothelial vWF. In addition, platelet GPVI and/or integrin α2ß1 binding to collagen is required for 
platelet adhesion and leads to activation of the αIIbß3 receptor, thromboxane A2 production and release of dense 
and α granules containing ADP, vWF, fibrinogen, fibronectin, p-selectin and interleukin 1 beta further enhancing 
platelet activation and aggregation. In addition, platelets are activated by other agonists such as thrombin. B) 
Finally, activated αIIbß3 receptor binds soluble vWF, fibrinogen and fibrin and mediates cross-linkage and thus, 
platelet aggregation. ADP = adenosine diphosphate, GP = glycoprotein, vWF = von Willebrand factor. Source:12  
 
Adenosine diphosphate and the P2Y receptors 
The released of ADP from dense granules, stimulated by collagen and thrombin,110 causes 
significant amplification of platelet activation by auto- or paracrine binding to platelet purine 
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receptors P2Y1111 and P2Y12.112 Purine and pyrimidine receptors are divided in P1 receptors 
selective for adenosine and P2 receptors, which are further divided in the ligand-gated ion 
channels P2X receptors and the G protein-coupled P2Y receptors.113 Binding of ADP to the 
metabotropic Gq-coupled P2Y1 receptor results in phospholipase C activation, subsequent 
increase of inositol triphosphate and rise of cytosolic calcium from intracellular stores.113 
Instead, activation of the metabotropic Gi-coupled P2Y12 receptor leads to an inhibition of the 
adenylyl cyclase and subsequent decrease of cyclic adenosine monophosphate.113 In 
addition, the P2Y12 receptor activates phosphoinositide 3-kinase (PI3K) and thereby the αIIbß3 
receptor.114 Activation of the P2Y1 leads to platelet shape change and transient aggregation, 
whereas activation of the P2Y12 receptor results in dense granule secretion and sustained 
platelet aggregation.110 In summary, activation of both receptors is necessary to grant full 
platelet aggregation since blockade of each receptor individually reduces platelet 
aggregation.115 Interestingly, inhibition of both receptors in parallel shows synergistic 
effects.116 
 
3.6 P2Y12 receptor antagonists 
Due to the crucial role of platelets in arterial thrombus formation, platelet antagonists are 
routinely used in the clinic to reduce thrombogenesis and prevent cardiovascular 
complications such as myocardial infarction (MI) and stroke.6 Beside from established 
platelet antagonists including the cyclooxygenase-1 antagonist aspirin6, integrin αIIbß3 
antagonists117 and emerging inhibitors of GPIV118, GPIb119 and thromboxane A2 receptors120, 
platelet ADP receptor P2Y12 antagonists have been shown to reduce major adverse cardiac 
events in large clinical trials.121-124 Currently four P2Y12 receptor antagonists are approved for 
clinical use including clopidogrel, prasugrel, ticagrelor and cangrelor, whereas the first 
approved P2Y12 receptor antagonist ticlopidine has been replaced due to adverse 
haematological side effects125 and development of elinogrel was discontinued recently.126 
P2Y12 receptor antagonists can be divided into thienopyridines including ticlopidine, 
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clopidogrel and prasugrel, in cyclopentyl-triazolo-pyrimidines including ticagrelor and in the 
adenosine triphosphate analogue cangrelor.127  
 
The thienopyridines clopidogrel and prasugrel 
Thienopyridines are indirect pro-drugs requiring conversion to the active metabolite by 
hepatic cytochrome P450 enzymes before irreversibly binding the P2Y12 receptor.127 
Pharmacokinetic and pharmacodynamic properties differ significantly among P2Y12 receptor 
antagonist. Clopidogrel not only exhibits weak inhibition of ADP-induced platelet aggregation 
with great inter-individual variability128 but also 15 to 30 % of patients respond only marginally 
to clopidogrel treatment.129 Importantly, higher platelet reactivity to ADP despite clopidogrel-
treatment is associated with an increased risk of major adverse cardiac events.129 Such non-
responsiveness might be due to incompliance, differences in intestinal absorption and P2Y12 
receptor polymorphisms;129 however, it has been proposed that variations in the cytochrome 
P450 3A4 considerably influences hepatic activation of clopidogrel.130 Surprisingly, treatment 
adjustment in non-responders to clopidogrel did not improve cardiovascular outcome.131 
Compared to clopidogrel, prasugrel shows a faster onset and higher level of platelet inhibition 
as well as a reduced inter-individual variability and lower non-responsiveness132,133 due to a 
more efficient conversion of prasugrel to its active metabolite.134 Consequently, prasugrel, 
compared with clopidogrel, reduced the primary composite endpoint, the rate of death from 
cardiovascular causes, non-fatal MI, or non-fatal stroke in ACS patients.122 On the other 
hand, prasugrel increased major bleeding events and therefore, did not reduce overall 
mortality in these patients.122 
 
The cyclopentyl-triazolo-pyrimidine ticagrelor 
Ticagrelor and cangrelor are direct acting drugs, do not need hepatic transformation and bind 
to the P2Y12 receptor reversibly.127 Ticagrelor, similarly to prasugrel, exhibits a faster onset, a 
greater level of and a more rapid offset of inhibition of ADP-induced platelet aggregation.135 
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Due to reversible binding, ticagrelor may be more protective from platelet aggregation in 
patients with high platelet turnover due to a more sustained platelet inhibition of newly formed 
(reticulated) platelets.136 Patients with higher number of reticulated platelets are at higher risk 
for cardiovascular events.137 Correspondingly, aggregation of immature platelets correlated 
with prasugrel, but not ticagrelor-treated patients with ACS.138 In large randomized clinical 
trials, ticagrelor proved higher efficacy, compared with clopidogrel in ACS patients; ticagrelor 
reduced the primary composite endpoint, death from vascular causes, MI and stroke without 
increasing the primary safety endpoint, major bleedings although fatal intracranial and non-
intracranial bleeds were higher in ticagrelor-treated patients121. Importantly, ticagrelor, 
compared with clopidogrel, also reduced overall mortality.121 Furthermore, in patients with 
prior MI, ticagrelor, compared with clopidogrel, reduced cardiovascular death, MI and stroke, 
but also increased major bleedings.139 
 
Pleiotropic effects of P2Y12 receptor antagonists 
Thienopyridines were shown to have multiple pleiotropic effects.140 In apolipoprotein E-
deficient mice prone to atherosclerosis, clopidogrel treatment reduced atherosclerotic lesion 
size by roughly one third, compared to control animals.141 Anti-inflammatory properties have 
been described for prasugrel; in a mouse model for endotoxic shock syndrome, prasugrel 
reduced platelet p-selectin expression and platelet-leukocyte interaction as well thromboxane 
2 and TNF-α production.142 Both, ticlopidine and clopidogrel were found to mediate 
endothelial-dependent vasodilatation in pre-contracted arteries of rats.143 In patients with 
coronary artery disease and peripheral endothelial dysfunction, single dosages of clopidogrel 
dose-dependently reduced endothelial dysfunction as assessed by flow-mediated dilatation 
of the brachial artery.144  
Like for thienopyridines, pleiotropic effects have been described also for ticagrelor.140,145 In 
addition to the P2Y12 receptor, ticagrelor, but not thienopyridines or cangrelor, binds to the 
equilibrative nucleoside transporter 1 (ENT1),146 which is expressed in red blood cells among 
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many others,147 and reduces adenosine uptake.146 Consequently, ticagrelor decreased 
adenosine uptake in human red blood cells148 and increased plasma levels of adenosine in 
ACS patients treated with ticagrelor.149 Adenosine inhibits platelet activation150 and was found 
to contribute to platelet inhibition in human whole blood treated with ticagrelor.151 
Furthermore, ticagrelor, but not prasugrel or clopidogrel, reduced VSMC contraction in rats;152 
Treatment with ticagrelor revealed anti-inflammatory properties by reducing pulmonary 
oedema, neutrophil recruitment and lung damage in mice exposed to experimental 
abdominal sepsis.153 In addition, ticagrelor, unlike clopidogrel, reduced MI in rats154 and in 
pigs in an adenosine-dependant manner.155 In patients with prior ACS, ticagrelor, compared 
with clopidogrel and prasugrel, improved peripheral arterial function after forearm 
ischemia.156 Such additional pleiotropic effects may in part contribute to the differences in 
outcomes observed in randomized controlled trials comparing P2Y12 inhibitors. 121,139 
 
3.7 Atherothrombosis 
Arterial thrombosis on top of an atherosclerotic lesion is the key event in ACS and results 
from interactions between the vessel wall, blood cells including platelets, red blood cells and 
leukocytes and the coagulation system.86,157-160  
 
Atherosclerotic plaques 
Complex atherosclerotic lesions prone to rupture and to cause arterial thrombosis usually 
present a thin fibrous caps, are large in size and cause a small luminal area;161 they typically 
cause expansive vascular remodelling and exhibit low calcification.162 Furthermore, they 
contain a large lipid core, numerous leukocytes and fewer VSMC.163 
During the early stage of plaque development, atherosclerosis causes vascular enlargement 
by expansive growth, which compensates vascular stenosis through the newly formed 
plaque; therefore, stenosis occurs late during plaque development.164 Plaque rupture rather 
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than superficial erosions of the fibrous caps overlying the lipid or so-called necrotic core, 
causes the majority of fatal coronary thrombosis.165 
Plaque rupture is associated with thin fibrous caps166 and its stability is believed to be 
mediated primarily through collagen, which is synthetized by VSMCs and degraded by some 
matrix-metalloproteinases.159 Accumulation of T-lymphocytes and macrophages, however, 
reduces collagen synthesis by inhibiting VSMCs and increase collagen breakdown by 
producing matrix-metalloproteinases, respectively.159 In contrast to plaque rupture, plaque 
erosion is believed to be triggered primarily by endothelial apoptosis due to increased 
oxidative stress from activated leukocytes, which also increases up-regulation of pro-
coagulant TF.159 Interestingly, statin therapy not only reduces plasma low-density lipoprotein 
and lipid content of atherosclerotic plaques but also decreases atherosclerotic plaque 
macrophage activity, which may contribute to its well-defined cardiovascular protective 
effects.167 Also, anti-inflammatory therapy with low-dose colchicine reduced cardiovascular 
events in patients with stable coronary artery disease168 highlighting the importance of 
inflammation in atherosclerosis and subsequent arterial thrombosis. 
 
Platelet adhesion, activation and recruitment 
Upon plaque erosion or rupture due to underlying inflammatory mechanisms159, 
subendothelial extracellular matrix is exposed. In high shear conditions, as occurring in the 
arterial vasculature, vWF is essential for platelet tethering108 and subsequent binding of 
various platelet receptors to subendothelial collagen, fibrinogen and laminin enables platelet 
adhesion109. Platelet adhesion triggers release of platelet granules containing ADP and 
thromboxane, which enhances platelet activation.12,109 Next, integrin αIIbß3 receptors become 
activated and, together with platelet GPIb, binds vWF and other soluble molecules, whereby 
additional platelets are recruited and aggregate at the side of plaque erosion or rupture.12,107  
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Initiation, amplification and propagation of the coagulation cascade 
In parallel to platelet recruitment, the coagulation cascade is initiated by TF.157 Exposure of 
TF and subsequent binding of factor VII/factor VIIa85 activates factor IX and factor X.85 Next, 
factor Xa forms the prothrombinase complex with factor Va on TF-containing containing 
cells89, which leads to the formation of small amounts of thrombin.91  
 
Following initiation of the coagulation cascade, thrombin not only leads to platelet activation 
via cleavage of protease-activated receptors 1 and 492 but also activates co-factor V, co-
factor VIII and factor XI on platelet surfaces thereby amplifying the procoagulant signal.90 
During the propagation phase, large amounts of thrombin are produced.90 After thrombin-
mediated activation of factor XI to XIa, factor XIa activates factor IX to IXa, which binds factor 
VIIIa and thus forms the tenase complex activating factor X to Xa; factor Xa complexes with Va 
and increases thrombin.86 Finally, thrombin transforms fibrinogen to fibrin, which 
subsequently polymerizes to fibrin strands.91 Lastly, after activation by thrombin among 
others, factor XIIIa stabilizes polymerized fibrin strands to form a stable platelet clot.169 
 
3.8 State of research in the field  
In addition to aspirin, P2Y12 receptor antagonists including clopidogrel, prasugrel and 
ticagrelor are crucial to reduce MI, stroke and CV death in patients suffering an ACS as 
shown in large randomized controlled trials.121-123 Both prasugrel and ticagrelor exhibit 
greater inhibition of ADP-induced platelet aggregation, as compared with clopidogrel.132,135 
Yet, despite comparable efficacy in platelet inhibition170 only ticagrelor, but not prasugrel, 
reduced overall mortality in ACS patients, as compared with clopidogrel.121,122 Recently 
described pleiotropic anti-inflammatory153 and vasodilative effects152 of ticagrelor as well as 
the ability to inhibit the adenosine transporter ENT1, may in part explain this observation. 
Nevertheless, P2Y12 receptors are not only expressed in platelets but also in the vessel 
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wall171 and platelet-independent vascular effects of P2Y12 antagonists on arterial 
thrombogenesis remain unknown.  
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6 Summary 
6.1 Ticagrelor, but not clopidogrel active metabolite, reduces endothelial 
tissue factor via proteasomal degradation 
In our initial study we showed that ticagrelor, unlike CAM, dose-dependently reduced TF 
protein expression as well as TF enzyme activity in TNF-α-stimulated HAECs indicating local 
antithrombotic properties of ticagrelor on the human endothelium1 in addition to its well-
described anti-platelet effects.2 By investigating the underlying molecular mechanisms, we 
found that the reduction in endothelial TF expression by ticagrelor was reversed by 
wortmannin and rapamycin suggesting the involvement of the signalling molecules PI3K and 
p70s6 kinase.1 Furthermore, inhibition of proteasomes using MG-132 reversed the effects of 
ticagrelor on TF expression in HAECs.1  On the other hand, ticagrelor did not decrease TF 
mRNA nor did it affect TF mRNA stability indicating that ticagrelor reduced endothelial TF 
expression by proteasomal degradation rather than mRNA modification.1 Interestingly, the 
observed effects of ticagrelor were mediated independently of the ADP receptor P2Y12,1 the 
target receptor of ticagrelor on platelets3, since it was not expressed in HAECs, neither on 
the mRNA nor on the protein level.1 Recently it was shown that ticagrelor also inhibits the 
adenosine transporter ENT1,4 which mediates cellular uptake of adenosine in red blood cells, 
among others,5 thereby increasing adenosine plasma levels in patients treated with 
ticagrelor.6 These findings led to the hypothesis that ticagrelor may inhibit ENT1, known to be 
expressed in endothelial cells,7 and subsequently increases extracellular adenosine levels, 
which in turn affect TF expression through one of the four endothelial adenosine receptors8. 
In line with previous reports,9 adenosine dose-dependently decreased TF expression in TNF-
α-stimulated HAECs.1 However, adenosine, unlike ticagrelor, exerted its effect via a reduction 
of TF mRNA.1 In contrast to ticagrelor, dipyridamole, a slightly more potent ENT1 inhibitor4, 
did not reduce TF protein expression in HAECs and thus, not mimic the effects of ticagrelor.1 
Lastly, inhibition of all adenosine receptors individually or in combination did not reverse the 
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reduction of TF mediated by ticagrelor thereby disproving the ENT1 hypothesis in endothelial 
cells.1 
 
6.2 Ticagrelor, compared with clopidogrel, decreases endothelial tissue 
factor expression and arterial thrombosis in mice 
Next, we investigated the physiological relevance of our in vitro findings in a mouse model of 
photochemical-induced arterial thrombosis and found that ticagrelor, but not clopidogrel, at 
physiological plasma concentrations, reduced TF expression in the endothelium of common 
carotid arteries.1 Furthermore, ticagrelor prolonged time to arterial occlusion, compared with 
clopidogrel, in mice.1 Plasma TF activity and endogenous thrombin potential, on the other 
hand, were comparable among the treated groups.1 Likewise, platelet aggregation in 
response to ADP was inhibited to similar extents in both mice treated with ticagrelor and 
clopidogrel.1 These findings indicate that ticagrelor exerts more potent antithrombotic 
properties, compared with clopidogrel, which was associated with a local reduction of 
endothelial TF expression and independent of changes in plasma TF activity, systemic 
coagulation or inhibition of ADP-induced platelet aggregation.1  
 
6.3 Ticagrelor, unlike clopidogrel active metabolite, reduces thrombogenicity 
in atrial fibrillation patients 
AF triggers thrombus formation in LAA leading to systemic embolism such as ischemic stroke 
causing substantial morbidity and mortality.10 Although anticoagulant treatment is considered 
standard therapy to prevent thromboembolic complications10, patients with AF frequently 
have comorbidities such as ACS requiring antiplatelet therapy.11 Therefore, we studied 
whether certain P2Y12 receptor antagonist may possess local antithrombotic properties in 
endocardial cells isolated from LAA of AF patients.12 Recently it was shown that the 
thrombotic factors TF and plasminogen activator inhibitor-1 (PAI-1) are expressed to a higher 
extent in left, as compared with right atrial appendages, which may in part explain the greater 
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thrombogenicity observed in LAA.13 In accordance with our previous findings in HAECs and a 
mouse model of arterial thrombosis1 we found that ticagrelor, unlike CAM, reduced TF and 
PAI-1 protein expressions as well as enzyme activities in TNF-α-stimulated LAA endocardial 
cells isolated from AF patients.12 On the other hand we did not observe different expression 
levels of TFPI, the physiological antagonist of TF.12 Indeed, this translational study indicates 
local antithrombotic properties of ticagrelor, which may lower thrombogenicity in AF 
patients.12  
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7 Discussion 
7.1 Ticagrelor exhibits platelet-independent antithrombotic effects on the 
endothelium 
Cardiovascular disease including coronary artery disease and stroke among others is the 
leading cause of death in both men and women in Europe.14 Arterial thrombus formation 
following rupture of an atherosclerotic plaque is the key pathophysiological mechanisms 
leading to an ACS.15 Platelets, in addition to the coagulation system, are crucially involved in 
thrombus formation and inhibition of platelet aggregation has been proven to reduce 
thrombogenesis and thus MI and stroke.16-19 In 1988 the second international study of infarct 
survival (ISIS-2) study showed that platelet inhibition by aspirin reduces non-fatal MI, non-
fatal stroke and vascular mortality, compared with placebo.16 Later, dual antiplatelet therapy 
(DAPT) using the P2Y12 receptor antagonist clopidogrel in addition to aspirin was reported to 
further reduce non-fatal MI, stroke and CV death in the Clopidogrel in Unstable Angina to 
Prevent Recurrent Events (CURE) study.17 In more recent years, however, newer 
generations of P2Y12 receptor antagonists have evolved and were compared with the 
thienopyridine clopidogrel.18,19 Prasugrel is a third generation thienopyridine and like 
clopidogrel requires cytochrome P450 metabolism in order to form its active metabolite, 
which irreversibly binds the platelet ADP receptor P2Y12.2 Yet, prasugrel only requires a one-
step activation, as compared with the two-step activation of clopidogrel20 and platelet 
inhibition occurs faster and to a higher extend; also, inter-individual variability and non-
responsiveness to prasugrel is lower.21,22 Consequently, prasugrel reduced the incidence of 
death from cardiovascular causes, non-fatal MI, or non-fatal stroke in patients with ACS, as 
compared with clopidogrel.19 Nevertheless, prasugrel also increased major bleeding rates 
and thus, overall mortality was comparable in prasugrel- and clopidogrel treated patients.19 In 
contrast, ticagrelor is a cyclopentyl-triazolo-pyrimidine, which does not require cytochrome 
P450 activation and binds the P2Y12 receptor directly and reversibly2. Like prasugrel, 
ticagrelor displays faster and greater inhibition of ADP-induced platelet aggregation23 and 
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inhibits newly formed platelets more efficiently in patients with high platelet turnover24. 
Correspondingly, ticagrelor, compared with clopidogrel, further reduced the incidence of 
death from vascular causes, MI and stroke in ACS patients in the Platelet Inhibition and 
Patient Outcomes (PLATO) study.18 Importantly, major bleedings were not higher and 
ticagrelor reduced overall mortality.18 Despite the fact that both prasugrel and ticagrelor show 
greater platelet inhibition compared with clopidogrel,2 only ticagrelor reduced overall 
mortality18,22. Therefore, we hypothesized that platelet-independent effects of ticagrelor may 
contribute to this observation. 
Indeed, we found that ticagrelor reduced endothelial TF expression and activity by 
proteasomal degradation in HAECs and that ticagrelor decreased endothelial TF expression 
in murine arteries subsequently prolonging time to arterial occlusion in mice, compared with 
clopidogrel.1 Furthermore, ticagrelor lowered TF and PAI-1 expression in endocardial cells 
isolated from LAA of AF patients.12 These results strongly indicate local antithrombotic 
properties of ticagrelor on endothelial and endocardial cells and may in part explain the 
reduced mortality observed in PLATO. 
 
7.2 Ticagrelor-mediated tissue factor reduction in endothelial cells and its 
underlying molecular mechanisms 
We found that ticagrelor, but not CAM, concentration-dependently reduced TF expression as 
well as TF activity in HAECs and subsequently investigated the underlying molecular 
mechanisms.1 We found that the signalling molecules PI3K and p70s6 were involved in the 
reduction of TF protein expression by ticagrelor.1 This observation pointed towards an 
involvement of the P2Y12 receptor, a metabotropic G-protein coupled receptor linked to the 
downstream signalling molecule PI3K in platelets25. Nevertheless, we did not detected P2Y12 
mRNA or protein in endothelial cells.1  
Recently, platelet- as well as P2Y12 receptor-independent pleiotropic effects have been 
described for ticagrelor.26 Unlike thienopyridines, ticagrelor also binds to the adenosine 
  52 
transporter ENT1,4 which is expressed in red blood cells and endothelial cells among 
others.5,7 ENT1 mediates adenosine uptake in red blood cells, which was decreased by 
ticagrelor in vitro27 and correspondingly, higher adenosine plasma levels were found in ACS 
patients after treatment with ticagrelor.6 Adenosine is known to inhibit platelet aggregation28 
and indeed, adenosine contributed to the inhibition platelet aggregation in whole blood 
treated with ticagrelor29. Since both ENT1 and adenosine receptors are expressed in 
endothelial cells7,8, we tested the hypothesis that ticagrelor inhibits ENT1 in HAECS 
increasing extracellular levels of adenosine and subsequently reducing TF via endothelial 
adenosine receptors. Indeed, adenosine decreased endothelial TF expression; however; this 
observation was mediated via a reduction in TF mRNA rather than proteasomal degradation 
as observed with ticagrelor1. Also, the ENT1 inhibitor dipyridamole4 did not mimic, and 
inhibition of adenosine receptors did not reverse the effects of ticagrelor on TF expression 
suggesting that our observations were occurring independently of ENT1.1 Indeed, ticagrelor 
shows side effects similar to adenosine such as dyspnoea18,30,31 and increased adenosine 
levels through inhibition of ENT1 by ticagrelor4 represent a plausible explanation for this 
finding. Nevertheless, several arguments speak against this hypothesis. Firstly, the ENT1 
inhibitor dipyridamole does not cause dyspnoea32,33 and secondly, the adenosine 
triphosphate analogue cangrelor, which, like ticagrelor, inhibits P2Y12 receptors reversibly but 
does not bind to ENT14 also causes dyspnoea, albeit to a lesser extent.34,35 These 
observation further support the concept that ticagrelor may exert additional mechanism 
beyond P2Y12 and ENT1 inhibition.  
Other molecular mechanisms potentially explaining our in vitro findings include direct binding 
of ticagrelor to adenosine receptors due to their molecular similarity. Indeed, ticagrelor shows 
low binding affinity to the adenosine receptors A1, A2a, A2b and A3; however clinical 
concentrations of ticagrelor are of neglectable functional relevance.4 Moreover, ticagrelor 
may exhibit binding affinity to other family members of the P2 purine and pyrimidine 
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receptors expressed in endothelial cells.36 However, to date no such interactions have been 
described. 
 
7.3 Ticagrelor and arterial thrombosis in vivo – relevance of endothelial 
tissue factor 
In C57BL/6 mice we found that ticagrelor reduced arterial thrombosis more effectively than 
clopidogrel and, correspondingly, that ticgrelor-treated mice showed lower endothelial TF 
expression.1 On the other hand, we did not observe differences in platelet aggregation or 
systemic coagulation including plasma TF activity and endogenous thrombin potential 
between the two groups.1 These results suggest that ticagrelor exerts local antithrombotic 
properties by reducing endothelial TF expression in addition to its well-described antiplatelet 
effects.1 
TF plays a crucial role in arterial thrombosis as it initiates the extrinsic coagulation cascade 
by activating factor VII37 followed by factor IX and X38 and subsequently thrombin; thrombin in 
turn, activates a positive feedback loop39 finally leading to large amounts of fibrin formation40 
in addition to platelet activation.41 TF is expressed in the entire vasculature including 
endothelial cells42, VSMC and adventitial cells43 as well as on circulating TF-containing 
microparticles released from endothelial cells44; In pathological conditions, such as high 
shear flow45 as occurring in a stenosed artery and during inflammation as occurring in 
atherosclerosis, TF expression is upregulated.46 Consequently, TF is detected in the necrotic 
core of atherosclerotic plaques.43,47,48 Vascular, rather than blood cell-derived TF appears to 
play a relevant role in arterial thrombus formation.49 Day and colleagues showed that mice 
expressing low amounts of TF in bone marrow cells did not have prolonged arterial occlusion 
times and that mice with TF deficiency that were transplanted with bone marrow cells 
expressing physiologic amounts of TF, did not have reduced arterial occlusion times.49 
Importantly, the group used the same experimental mouse model for arterial thrombosis as 
we did in our study, i.e. photochemical injury of the carotid artery by bengal rose.49 The 
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relevance of TF in arterial thrombosis was further supported by Pawashe et al. showing that 
anti-TF antibody treatment decreased arterial thrombosis in common carotid arteries of 
rabbits50. Lastly, clinical studies found an association of TF with cardiovascular risk factors51-
54 and the incidence of MI.55 
Whether indeed the decrease of endothelial TF expression by ticagrelor entirely explains the 
reduction in arterial thrombosis observed in mice remains to be proven by rescue 
experiments. Since the exact mechanisms leading to TF degradation are not entirely 
understood, it appears difficult to rescue endothelial TF reduction in vivo without affecting 
other sources of TF. On the other hand, one would expect no differences in arterial thrombus 
formation in endothelial-specific TF knockout mice treated with ticagrelor or clopidogrel and 
exposed to photochemical injury of the common carotid arteries. Yet, we did not have access 
to such a mouse strain. 
 
Although we have ruled out other potential and relevant mechanisms explaining the 
differences in arterial thrombus formation between ticagrelor- and clopidogrel-treated 
rodents, such as alterations in platelet aggregation, plasma TF activity and systemic 
coagulation, additional possible explanations remain. Kirby et al. reported that inhibition of 
platelet aggregation by NO, which is usually rather low, increased significantly in the 
presence of the P2Y12 receptor antagonist prasugrel active metabolite or ticagrelor.56 This 
finding was explained by synergistic effects of NO and P2Y12 receptor inhibition on the 
reduction of the downstream signalling molecule PI3K.56 NO is produced in endothelial cells 
by endothelial NO synthase57 and inducible NO synthase during inflammation58. Interestingly, 
we have previously shown that ticagrelor, unlike CAM, dose-dependently increases 
phosphorylation of endothelial NO synthase at the activation side serine 1177.59 In line with 
our findings, treatment with ticagrelor augmented myocardial NO synthase in rats.60 
Increased phosphorylation of endothelial NO synthase may result in higher concentration of 
NO at the vessel wall and may contribute to higher platelet inhibition in vivo. 
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Drug dosages of P2Y12 receptor antagonists in rodents 
In humans, ticagrelor, compared with clopidogrel, exerts greater inhibition of ADP-induced 
platelet aggregation23. Therefore, different effects on MI, stroke and CV death between 
clopidogrel- and ticagrelor-treated patients18,30 may be due to different platelet inhibitory 
effects. To rule out platelet-dependent effects in our study we selected dosages of ticagrelor 
and clopidogrel that resulted in comparable inhibition of ADP-induced platelet aggregation.1 
Importantly, we performed platelet aggregometry in whole blood as it was recently reported 
that adenosine contributes to whole blood platelet inhibition in the presence of ticagrelor.29 In 
order to show that our experiments were performed at minimal drug concentrations and that 
none of the drugs were used at excessively high concentrations, we performed dose 
response experiments and found that reducing drug dosages by only one third resulted in 
residual and comparable platelet reactivity in ticagrelor- and clopidogrel-treated animals.1 
Besides, dosages in our in vitro and in vivo experiments were chosen so as to reflect plasma 
concentration found in humans. Recommended dosages in cardiovascular patients for 
clopidogrel and ticagrelor represent a loading dosage of 300 – 600 mg followed by 75 mg 
once daily and a loading dosage of 180 mg followed by 90 mg twice daily, respectively.11 
Thus, maintenance dosages differ 2.4 fold. Such dosages provide plasma concentration of 
0.16 – 0.18 uM of clopidogrel active metabolite and 1 – 1.5 uM of ticagrelor in humans2. 
Likewise, drug dosages in our study differed 2.5 fold (ticagrelor 0.15% vs. clopidogrel 
0.06%).1 However, unlike in humans,23 these dosages resulted in equivalent platelet 
inhibition in mice1, which was also in line with previous findings in rats.60 In addition, we 
evaluated ticagrelor plasma concentration in mice and found concentrations of 2.7±0.7 uM,1 
which were comparable to humans.2 
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8 Outlook 
Here we report that ticagrelor, unlike CAM, reduces endothelial TF by proteasomal 
degradation in vitro.1 On a molecular level we found that the effect of ticagrelor on TF was 
mediated by the signalling pathways PI3K and p70s6 kinase.1 We have shown that the 
observed effects were independent of the P2Y12 receptor as well as ENT1 indicating that 
other mechanisms may be involved.1 Yet, specific additional target receptors of ticagrelor 
remain to be determined. To assess the physiological relevance of our in vitro data in vivo, 
we showed that ticagrelor, unlike clopidogrel, reduced endothelial TF expression in common 
carotid arteries and prolonged arterial occlusion times in mice; further, we ruled out other 
potential and relevant mechanisms, which could have contributed to this observation 
including platelet aggregation, plasma TF activity and systemic coagulation.1 In order to 
finally prove the relevance of endothelial TF in our experiments, a rescue experiment 
specifically preventing the reduction of endothelial TF by ticagrelor in vivo, without affecting 
other sources of TF, appears essential. 
Our study indicates local antithrombotic effects of ticagrelor at the vessel wall in addition to 
its antiplatelet effects.1 Such properties may have contributed to the reduction of clinical 
events including MI and stroke in ACS patients treated with ticagrelor in clinical trials.18,30 On 
the other hand, dual antithrombotic effects of ticagrelor may contribute to an increased 
bleeding risk. Although ticagrelor did not augment total major bleeding events, fatal 
intracranial bleeds were higher in ACS patients treated with ticagrelor, compared with 
clopidogrel.18 Whether this observation may be due to higher platelet inhibition23 or due to the 
local antithrombotic properties of ticagrelor1 remain speculative.  
 
In a subsequent study we investigated whether the antithrombotic properties displayed by 
ticagrelor12 could also be relevant in AF patients. Previously it was reported that LAA 
endocardial cells express higher levels of procoagulant TF and PAI-1, as compared with right 
atrial appendages, which may contribute to the higher thrombogenicity observed in LAA.13 
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Therefore, we investigated whether ticagrelor or CAM may affect TF or PAI-1 expression in 
LAA endocardial cells isolated from AF patients. Indeed, we found that ticagrelor, but not 
CAM, reduced TF and PAI-1 protein expressions as well as enzyme activities indicating local 
antithrombotic mechanisms in AF patients.12 AF is a common cardiac arrhythmia, which is 
associated with an increased risk of stroke and mortality and oral anticoagulation is the 
treatment of choice to reduce thromboembolic complication.10 Indeed, anticoagulation has 
been shown to be superior to antiplatelet therapy (single or DAPT).61 Yet, newer and more 
potent generations of P2Y12 receptor antagonists including ticagrelor have not been 
compared to oral anticoagulation in AF patients in randomized clinical trials. The described 
local antithrombotic properties of ticagrelor in LAAs of AF patients may be of clinical 
relevance and may affect thrombogenicity in these patients;12 however, this hypothesis 
needs to be addressed in additional clinical studies. 
Frequently, AF patients have comorbidities such as ACS and require both anticoagulant and 
antiplatelet therapy, referred to as triple anticoagulation.11 In such patients, ticagrelor may be 
the preferred choice in order to reduce thromboembolic complications. Triple anticoagulation 
on the other hand increases bleeding complications substantially and choosing the ideal 
treatment to prevent thrombotic events without causing bleedings is challenging.11 In patients 
with an ACS receiving DAPT (aspirin and a thienopyridine), small dosages of oral 
anticoagulants are sufficient to increased bleeding rates significantly.62 Consequently, in 
patients with anticoagulant treatment undergoing percutaneous intervention requiring DAPT, 
single (clopidogrel) versus DAPT reduced bleeding complications significantly;63 however, 
although not statistical significant, higher rates of thrombotic events have been observed in 
the single antiplatelet therapy group.63 Therefore, it remains to be determined whether 
reducing triple antithrombotic therapy to oral anticoagulation and P2Y12 receptor inhibition is 
sufficient to sustain low thrombotic events. The local anti-thrombotic properties of ticagrelor 
appear beneficial in AF patients requiring platelet antagonists due to comorbidities such as 
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ACS; however, further clinical studies are required to prove the effectiveness and safety of 
newer generations of P2Y12 receptor antagonists such as ticagrelor in AF.64   
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9 Abbreviations 
ACS acute coronary syndrome 
ADP adenosine diphosphate  
AF atrial fibrillation 
CAM clopidogrel active metabolite 
CURE Clopidogrel in Unstable Angina to Prevent Recurrent Events 
CV cardiovascular 
CVD cardiovascular disease 
DAPT dual antiplatelet therapy 
eNOS endothelial nitric oxide synthase 
ENT1 equilibrative nucleoside transporter 1 
GP glycoprotein 
H2O2 hydrogen peroxide 
HAECs human aortic endothelial cells 
ISIS-2 second international study of infarct survival 
LAA left atrial appendage 
LDL low-density lipoprotein 
MI myocardial infarction 
NADPH nicotinamide adenine dinucleotide phosphate 
NO nitric oxide 
O2- superoxide anion 
OH hydroxyl radicals 
ONOO- peroxynitrite 
PAI-1 plasminogen activator inhibitor-1 
PGI2 prostacyclin 
PI3K phosphoinositide 3-kinase 
PLATO study of Platelet Inhibition and Patient Outcomes 
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ROS reactive oxygen species 
TF tissue factor 
TFPI tissue factor pathway inhibitor 
TNF-α tumor necrosis factor-alpha 
VCAM-1 vascular cell adhesion molecule-1 
VSMC vascular smooth muscle cells 
vWF von Willebrand factor 
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